20 June 2013
Keywords: medimmune, rsv, antibody, phase, iii, begun, trial
Article | 02 December 1996
MedImmune has begun a Phase III trial to evaluate the safety and
efficacy of MEDI-493, the firm's humanized monoclonal antibody ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 December 1996
25 November 1996
19 June 2013
© 2013 thepharmaletter.com